C-9JRAQu Biologics
Site Specific Immunomodulators, innate immunity, immunotherapy
trainingimmunotherapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-9JRA
C-9JRAC-9JRASite Specific Immunomodulators, innate immunity, immunotherapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Qu Biologics states that cancer can be fought by activating the body’s natural anti-cancer immune response. The company presents its Site Specific Immunotherapies (SSIs) as a novel, potentially safe and effective cancer therapeutic, argues that early human survival results are compelling, and expresses the belief that this approach could improve both quality of life and survival for millions of cancer patients.
SourceQu Biologics stated that chronic inflammation underlies many conditions, including cancer and autoimmune disease, and that activating the body’s immune system through its Site Specific Immunomodulators (SSIs) could reverse that inflammation. The company presented this as a fresh immunotherapeutic approach with the potential, if shown safe and effective, to improve survival and quality of life for patients with cancer and debilitating autoimmune diseases.
SourceQu Biologics states that it is developing Site Specific Immunomodulators (SSIs) as a new immunotherapeutic platform intended to activate the body's immune system and reverse the chronic inflammation it says underlies many conditions, including cancer and autoimmune diseases. It presents early compassionate-use experience as suggesting promising outcomes and frames its work as requiring further validation in controlled clinical trials.
SourceQu Biologics presents itself as a clinical-stage biopharmaceutical company developing cancer treatments that activate the body’s innate immune response, target the tissue or organ where the cancer is growing, and aim to reverse the immune suppression it says often underlies cancer growth and development.
SourceQu Biologics states that it is developing Site Specific Immunomodulators (SSIs) to activate the body’s immune system and reverse the chronic inflammation it says underlies many conditions, including cancer and immune-related diseases such as Crohn’s disease. The company presents preliminary compassionate-use findings as promising support for further controlled clinical trials and says its goal is to improve survival and quality of life for people with cancer and quality of life for people with debilitating immune-related diseases.
Source